Personalized Cancer Vaccine Shows Promise Against Pancreatic Tumors

BioNTech's mRNA-based treatment generated immune responses against pancreatic cancer cells in half of trial participants.
The treatment was co-developed by Roche's Genentech and targets pancreatic ductal adenocarcinoma, the most common form of pancreatic cancer.
Among participants with an immune response, there were no signs of cancer recurrence 18 months after surgery.
The treatment trains the body's immune system to recognize and attack pancreatic cancer cells.
If proven effective, the vaccine could provide a much-needed new tool against a cancer with poor survival rates.